Oncternal Therapeutics Inc (ONCT)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Oncternal Therapeutics Inc chart...

About the Company

oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic

CEO

James Breitmeyer

Exchange

NASDAQ

Website

http://www.oncternal.com/

$0M

Total Revenue

32

Employees

$24M

Market Capitalization

-3.77

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ONCT News

ONCT Oncternal Therapeutics, Inc.

3d ago, source: Seeking Alpha

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical ...

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

3d ago, source:

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today ...

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript

10d ago, source: Insider Monkey

Oncternal Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to Oncternal’s ...

Oncternal Therapeutics: Q4 Earnings Snapshot

11d ago, source: The Washington Post

SAN DIEGO — SAN DIEGO — Oncternal Therapeutics, Inc. (ONCT) on Thursday reported a loss of $9.2 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

11d ago, source:

Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of ...

Q4 2023 Oncternal Therapeutics Inc Earnings Call

10d ago, source:

Richard Vincent; CFO; Oncternal Therapeutics, Inc. Jim Breitmeyer; President and CEO; Oncternal Therapeutics, Inc. Carl Byrnes; Analyst; Northland Capital Markets Hartaj Singh; Analyst; Oppenheimer & ...

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

18d ago, source: Nasdaq

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies ...

Oncternal Therapeutics: Q4 Earnings Snapshot

11d ago, source: Times Union

SAN DIEGO (AP) — SAN DIEGO (AP) — Oncternal Therapeutics, Inc. (ONCT) on Thursday reported a loss of $9.2 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

Oncternal Therapeutics Inc ONCT

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript

10d ago, source: InvestingChannel on MSN

Q4 2023 Earnings Call Transcript March 7, 2024 Oncternal Therapeutics, Inc. isn’t one of the 30 most popular stocks among ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...